What Is Atrial Fibrillation
Atrial fibrillation (AFib) is the most common significant cardiac arrhythmia, affecting approximately 6 million Americans and 1 in 4 adults over age 80. In AFib, the heart's two upper chambers (atria) beat chaotically and rapidly instead of coordinating with the lower chambers (ventricles). This irregular, often rapid heart rhythm reduces the heart's pumping efficiency by 20–30%, allows blood to pool and potentially clot in the atria, and dramatically increases stroke risk — by 5-fold in patients not on anticoagulation therapy.
Hypertension as AFib's Primary Driver
Hypertension is the most common modifiable risk factor for developing AFib, contributing to approximately 20% of cases. Chronic high blood pressure causes structural remodeling of the left atrium — the chamber most involved in AFib. The left atrium enlarges, its walls stretch and develop fibrosis (scarring), and the normal electrical conduction system becomes disrupted, creating the chaotic electrical activity characteristic of AFib. This atrial remodeling develops over years and is directly proportional to the duration and severity of blood pressure control.
Blood Pressure Monitoring With AFib
Blood pressure monitoring is complicated in patients with AFib because the irregular rhythm makes most automated arm monitors less reliable — they are calibrated to detect regular heartbeats. Some validated monitors have specific AFib detection modes that improve accuracy in irregular rhythms. Look for monitors validated for use in AFib patients (check the validateBP.org list). Multiple readings averaged together generally provide more reliable estimates than single readings in AFib patients. Inform your doctor if your home readings seem highly variable.
Blood Pressure Targets in AFib Patients
The blood pressure target for AFib patients mirrors that for other high-risk cardiovascular patients: below 130/80 mmHg. ACE inhibitors and ARBs are particularly beneficial because they reduce atrial wall tension and fibrosis — potentially slowing the atrial remodeling that perpetuates AFib. Beta-blockers serve dual purpose: lowering blood pressure and controlling heart rate during AFib episodes. Aldosterone antagonists (spironolactone) are being studied for their anti-fibrotic effects on the atrium in hypertensive AFib patients.
